Assessing the benefit-harm balance at the bedside
BMJPublished 1 July 2004Open access
Yoon K. Loke
Citations17
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The authors need pragmatic ways of using the best available information to address the challenges of climate change and the impacts of natural disasters.
Keywords
MedicineEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
JAMATiming of New Black Box Warnings and Withdrawals for Prescription Medications
1,004 Citations2002Karen E. Lasser
To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market, Examination of the Physicians' Desk Reference for all new chemical entities approved by the US Food and Drug Administration between 1975 and 1999 is examined.
Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyValidity of the General Practice Research Database
586 Citations2003Susan S. Jick, James A. Kaye +7 more
The quality and completeness of the data that the GPRD contains are evaluated with extensive experience with this automated database.
BMJAn evidence based approach to individualising treatment
386 Citations1995Paul Glasziou, Les Irwig
Before making firm conclusions, the assumptions of fixed adverse effects and constant reduction in relative risk need to be checked.
BMJEfficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials
370 Citations2002Jonathan J Deeks, Lesley A Smith +1 more
Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability.
BMJJoining the DoTS: new approach to classifying adverse drug reactions
291 Citations2003Jeffrey K Aronson, R E Ferner
A new classification system for adverse drug reactions based on time course and susceptibility as well as dose responsiveness should improve drug development and management of adverse reactions.
British Journal of Clinical PharmacologyApplication of data mining techniques in pharmacovigilance
228 Citations2003Andrew M. Wilson, Lehana Thabane +1 more
The use of data mining techniques in knowledge discovery in medical databases is likely to be of increasing importance in the process of pharmacovigilance as they arelikely to be able to detect signals earlier than using current methods.
The LancetProvision of information about drug side-effects to patients
155 Citations2002DC Berry, Peter Knapp +1 more
Until further work is done on how patients taking the drugs interpret these terms, the terms should not be used in drug information leaflets.
BMC Clinical PharmacologyReporting of adverse drug reactions in randomised controlled trials – a systematic survey
129 Citations2001Yoon K. Loke, Sheena Derry
BMJBalancing benefits and harms in health care
104 Citations2003Luis Gabriel Cuervo, Mike Clarke
Randomised controlled trials are the best way to evaluate small to moderate effects of healthcare interventions, but they are not always suitable to evaluate harms, and this was made clear during a recent meeting jointly organised by the Cochrane Collaboration and BMJ Knowledge in London.
The LancetReporting of adverse drug reactions by nurses
103 Citations2003Sally Morrison–Griffiths, Thomas Walley +3 more
It is suggested that nurses, who form the largest proportion of health-care staff in the UK, can play a valuable part in improvement of pharmacovigilance.
BMJAssessment of therapeutic safety in systematic reviews: literature review
94 Citations2001E. Ernst, M.H. Pittler
British Journal of Clinical PharmacologyNew active substances authorized in the United Kingdom between 1972 and 1994
73 Citations1998David Jefferys, Diane Leakey +3 more
There is marked heterogeneity in the annual rates of authorisation of new active substances, and the provisional nature of assessments about safety at the time when a new active substance is introduced into routine clinical practice is confirmed, confirming the importance of pharmacovigilance.
BMJBenefits and harms of drug treatments
53 Citations2004Jan P. Vandenbroucke
Observational studies and randomised trials should learn from each other to improve the quality of research and reduce the amount of uncertainty in clinical practice.
BMJReporting of adverse drug reactions by hospital pharmacists: pilot scheme: Table 1
40 Citations1997A. Lee, D. Nicholas Bateman +3 more
The value of including pharmacists in a pilot scheme in which any report of a suspected adverse drug reaction signed by a fully registered hospital pharmacist working in the Northern region was sent to the Northern Regional Monitoring Centre was assessed.
British Journal of Clinical PharmacologyAspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient
19 Citations2003Yoon K. Loke, Alastair Bell +1 more
Estimating benefit and harm by taking into account the baseline risks in each individual allows patients and doctors to judge for themselves the magnitude of the trade-offs involved in taking aspirin.
BMJDrug companies should report side effects in terms of frequency
8 Citations1996Robert Bracchi
Doctors would be helped in advising their patients if the adverse effects of a drug were categorised in categories to help them balance the risks, costs, and benefits of drugs that they use.
BMJData protection, informed consent, and research
4 Citations2004Jonathan Fletcher, Joanna Marriott +1 more
The results support Peto et al's statement that it is not true that the public no longer tolerate access to their records by bona fide medical researchers and suggest that the balance between research requirements and patient confidentiality should be reassessed to bring the interpretation of legislation into line with patients' views.
BMJSomatostatin in bleeding oesophageal varices: Important information about trial was omitted
2 Citations1996S A Jenkins, I N Baxter
Journal of Internal MedicineDrug safety – important to us all!
1 Citations2001Lars Erik Böttiger
The tendency has generally been to sweep ADRs under the carpet, based on the two equally erroneous assumptions that the patients should not be scared and that the drug companies during their premarketing studies have been able to demonstrate all the inherent risks with their products.